Your browser doesn't support javascript.
loading
Effect of sevoflurane on the inflammatory response during cardiopulmonary bypass in cardiac surgery: the study protocol for a randomized controlled trial
Cardoso, Thiago Augusto A M; Kunst, Gudrun; Neto, Caetano Nigro; Júnior, José de Ribamar Costa; Silva, Carlos Gustavo Santos; Bastos, Gisele Medeiros; Borges, Jéssica Bassani; Hirata, Mario Hiroyuki.
Afiliación
  • Cardoso, Thiago Augusto A M; Dante Pazzanese Institute of Cardiology. Department of Surgery and Anesthesia. São Paulo. BR
  • Kunst, Gudrun; King's College Hospital NHS Foundation Trust. Intensive Care Medicine and Pain Therapy. London. GB
  • Neto, Caetano Nigro; Dante Pazzanese Institute of Cardiology. Department of Surgery and Anesthesia. São Paulo. BR
  • Júnior, José de Ribamar Costa; Dante Pazzanese Institute of Cardiology. Department of Interventional Cardiology. São Paulo. BR
  • Silva, Carlos Gustavo Santos; Dante Pazzanese Institute of Cardiology. Department of Surgery and Anesthesia. São Paulo. BR
  • Bastos, Gisele Medeiros; Dante Pazzanese Institute of Cardiology. Molecular Cardiology Research Laboratory. São Paulo. BR
  • Borges, Jéssica Bassani; Dante Pazzanese Institute of Cardiology. Molecular Cardiology Research Laboratory. São Paulo. BR
  • Hirata, Mario Hiroyuki; University of São Paulo. School of Pharmaceutical Sciences. Department of Clinical and Toxicological Analysis. São Paulo. BR
Trials ; Trials;22(1): 1-10, Jan. 2021. graf., tab.
Article en En | SES-SP, CONASS, SESSP-IDPCPROD, SES-SP | ID: biblio-1146759
Biblioteca responsable: BR79.1
Ubicación: BR79.1
ABSTRACT

Background:

Recent experimental evidence shows that sevoflurane can reduce the inflammatory response during cardiac surgery with cardiopulmonary bypass. However, this observation so far has not been assessed in an adequately powered randomized controlled trial.

Methods:

We plan to include one hundred patients undergoing elective coronary artery bypass graft with cardiopulmonary bypass who will be randomized to receive either volatile anesthetics during cardiopulmonary bypass or total intravenous anesthesia. The primary endpoint of the study is to assess the inflammatory response during cardiopulmonary bypass by measuring PMN-elastase serum levels. Secondary endpoints include serum levels of other pro-inflammatory markers (IL-1ß, IL-6, IL-8, TNFα), anti-inflammatory cytokines (TGFß and IL-10), and microRNA expression in peripheral blood to achieve possible epigenetic mechanisms in this process. In addition, clinical endpoints such as presence of major complications in the postoperative period and length of hospital and intensive care unit stay will be assessed.

Discussion:

The trial may determine whether adding volatile anesthetic during cardiopulmonary bypass will attenuate the inflammatory response.
Asunto(s)

Texto completo: 1 Colección: 06-national / BR Base de datos: CONASS / SES-SP / SESSP-IDPCPROD Asunto principal: Puente Cardiopulmonar / Sevoflurano / Anestésicos Tipo de estudio: Clinical_trials Idioma: En Revista: Trials Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 06-national / BR Base de datos: CONASS / SES-SP / SESSP-IDPCPROD Asunto principal: Puente Cardiopulmonar / Sevoflurano / Anestésicos Tipo de estudio: Clinical_trials Idioma: En Revista: Trials Año: 2021 Tipo del documento: Article